Literature DB >> 24655142

Phosphorothioate oligonucleotides: effectiveness and toxicity.

Tommaso Iannitti, Julio Cesar Morales-Medina, Beniamino Palmieri1.   

Abstract

BACKGROUND: Many experimental and clinical studies have focused on the antisense strategy. In this context phosphorothioate oligonucleotides are compounds addressed to hybridize to a targeted mRNA inducing a variety of effects including inhibition of the expression of proteins involved in different pathological processes and preventing translation.
METHODS: In this review, we provide an update on clinical efficacy and toxicological profile of phosphorothioate oligonucleotides used in experimental and clinical studies, also focusing on the use of the antisense strategy in the context of Duchenne muscular dystrophy which is a key pathology to study different aspects of this therapy. Pubmed/Medline was searched using the keyword "Phosphorotioate" combined with "Antisense", "Oligonucleotide" and "Duchenne muscular dystrophy".
CONCLUSIONS: Phosphorothioate oligonucleotide transient activation of the complement cascade represents the most evident toxicological response, as showed by in vivo studies. It is also known that many of these compounds induce a prolongation of activated partial thromboplastin time, a reaction which is often highly transient and proportional to the oligonucleotide plasma concentrations, making that effect clinically insignificant for the current treatment regimens. In summary, current evidence shows limited untoward effects and reversibility of the damage induced, at least for some of those compounds, with promising effectiveness for treatment of various pathologies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24655142     DOI: 10.2174/1389450115666140321100304

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  19 in total

1.  Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity.

Authors:  Chunsong Yu; Myunggi An; Evan Jones; Haipeng Liu
Journal:  Pharm Res       Date:  2018-02-08       Impact factor: 4.200

2.  Structurally constrained phosphonate internucleotide linkage impacts oligonucleotide-enzyme interaction, and modulates siRNA activity and allele specificity.

Authors:  Ken Yamada; Samuel Hildebrand; Sarah M Davis; Rachael Miller; Faith Conroy; Ellen Sapp; Jillian Caiazzi; Julia F Alterman; Loic Roux; Dimas Echeverria; Matthew R Hassler; Edith L Pfister; Marian DiFiglia; Neil Aronin; Anastasia Khvorova
Journal:  Nucleic Acids Res       Date:  2021-12-02       Impact factor: 16.971

Review 3.  MiRNA-SARS-CoV-2 dialogue and prospective anti-COVID-19 therapies.

Authors:  Mamta Panda; Elora Kalita; Satyendra Singh; Ketan Kumar; Abhishek Rao; Vijay Kumar Prajapati
Journal:  Life Sci       Date:  2022-07-01       Impact factor: 6.780

Review 4.  RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.

Authors:  Eunice L Lozada-Delgado; Nilmary Grafals-Ruiz; Pablo E Vivas-Mejía
Journal:  Life Sci       Date:  2017-08-31       Impact factor: 5.037

Review 5.  Current Status of Antisense Oligonucleotide-Based Therapy in Neuromuscular Disorders.

Authors:  Flavien Bizot; Adeline Vulin; Aurélie Goyenvalle
Journal:  Drugs       Date:  2020-09       Impact factor: 9.546

Review 6.  Revealing Nucleic Acid Mutations Using Förster Resonance Energy Transfer-Based Probes.

Authors:  Nina P L Junager; Jacob Kongsted; Kira Astakhova
Journal:  Sensors (Basel)       Date:  2016-07-27       Impact factor: 3.576

Review 7.  The Use of Tricyclo-DNA Oligomers for the Treatment of Genetic Disorders.

Authors:  Philippine Aupy; Lucía Echevarría; Karima Relizani; Aurélie Goyenvalle
Journal:  Biomedicines       Date:  2017-12-22

8.  Mesyl phosphoramidate antisense oligonucleotides as an alternative to phosphorothioates with improved biochemical and biological properties.

Authors:  S K Miroshnichenko; O A Patutina; E A Burakova; B P Chelobanov; A A Fokina; V V Vlassov; S Altman; M A Zenkova; D A Stetsenko
Journal:  Proc Natl Acad Sci U S A       Date:  2019-01-08       Impact factor: 11.205

9.  Exosome-mediated delivery of RNA and DNA for gene therapy.

Authors:  Radha Munagala; Farrukh Aqil; Jeyaprakash Jeyabalan; Raghuram Kandimalla; Margaret Wallen; Neha Tyagi; Sarah Wilcher; Jun Yan; David J Schultz; Wendy Spencer; Ramesh C Gupta
Journal:  Cancer Lett       Date:  2021-02-18       Impact factor: 8.679

Review 10.  Modified Nucleoside Triphosphates for In-vitro Selection Techniques.

Authors:  María A Dellafiore; Javier M Montserrat; Adolfo M Iribarren
Journal:  Front Chem       Date:  2016-05-04       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.